APA (7th ed.) Citation

CC, Z., MM, O., EP, P., R, G., PA, F., C, L., . . . GBE, J. (2019). Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. Journal of the American Academy of Dermatology, 80(1), 60. https://doi.org/10.1016/j.jaad.2018.05.040

Chicago Style (17th ed.) Citation

CC, Zouboulis, et al. "Long-term Adalimumab Efficacy in Patients with Moderate-to-severe Hidradenitis Suppurativa/acne Inversa: 3-year Results of a Phase 3 Open-label Extension Study." Journal of the American Academy of Dermatology 80, no. 1 (2019): 60. https://doi.org/10.1016/j.jaad.2018.05.040.

MLA (9th ed.) Citation

CC, Zouboulis, et al. "Long-term Adalimumab Efficacy in Patients with Moderate-to-severe Hidradenitis Suppurativa/acne Inversa: 3-year Results of a Phase 3 Open-label Extension Study." Journal of the American Academy of Dermatology, vol. 80, no. 1, 2019, p. 60, https://doi.org/10.1016/j.jaad.2018.05.040.